Givastomig + Nivolumab + Chemotherapy for Stomach Cancer

This trial explores whether adding givastomig to standard treatments can more effectively treat stomach and esophageal cancer. Researchers aim to determine if givastomig can extend the time patients live without their cancer worsening and to identify any side effects it may cause. The trial is open to individuals with advanced or metastatic stomach or esophageal cancer, provided their cancer cells have specific proteins and they have not received certain other treatments. Participants will receive treatments every few weeks and undergo regular check-ups and scans to monitor progress. As a Phase 2 trial, this research focuses on assessing the treatment's effectiveness in an initial, smaller group of people.

The trial information does not specify if you need to stop taking your current medications. It's best to discuss your specific medications with the study doctors to understand any potential interactions or requirements.

Research has shown that givastomig, when combined with nivolumab and chemotherapy, is generally well-tolerated. In earlier studies, patients tolerated givastomig at doses up to 12 mg/kg every two weeks without major issues. The most common side effects included manageable infusion reactions and some nausea. Another study noted a rare risk of stomach inflammation.

Researchers are excited about these treatments because they combine Givastomig, a novel agent, with the existing immunotherapy drug nivolumab and chemotherapy to tackle stomach cancer. Unlike standard treatments that primarily rely on chemotherapy, Givastomig acts by enhancing the body's immune response to target cancer cells more effectively. In the experimental arms, Givastomig is administered in varying doses and schedules, offering potential flexibility and customization in treatment approaches. By integrating this new approach, there's hope for improved outcomes and better management of stomach cancer, sparking significant interest in its potential benefits.

This trial will evaluate the effectiveness of different combinations of givastomig, nivolumab, and chemotherapy for treating stomach cancer. Studies have shown promising results when combining givastomig with nivolumab and chemotherapy, with 75% of patients experiencing tumor shrinkage or stabilization. The treatment proved even more effective for patients with certain proteins, such as PD-L1 and CLDN18.2. Earlier research found that givastomig was well tolerated and effective against this type of cancer. This evidence suggests that adding givastomig to standard therapy could offer a powerful new option for people with advanced stomach cancer.¹²⁴⁶⁷